1H 2018 Life Science Markets Update

Madison Park Group (MPG) actively tracks the life sciences software landscape and has been instrumental in strategic deals across the drug development & commercial spectrum

Through MPG’s time in the space, we’ve noticed a number of trends and developments:

• Vendors once confined to one segment of the life sciences value chain are starting to create horizontal platforms

• Software M&A and funding activity around landmark regulations (e.g. Drug Quality & Security Act, Sunshine Act) is coming to fruition

• Fragmented industry dominated by Oracle, Medidata and Veeva with an emerging class of scaled PE platforms (e.g. Bioclinica, Bracket, ERT) and aggressive CROs (e.g. IQVIA)

• Vendors are using high-touch services in conjunction with robust software in managing pharma workflows and compliance
• Standard for the Exchange of Nonclinical Data (SEND) regulations create a new market opportunity for pre-clinical software vendors